Protara Therapeutics (TARA) Profit After Tax (2013 - 2026)

Protara Therapeutics (TARA) has reported Profit After Tax for 14 consecutive years, with -$17.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 49.25% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$63.3 million (down 39.3% YoY), while the FY2025 annual figure was -$57.4 million, down 28.8% from the prior year.
• Profit After Tax eased to -$17.8 million in Q1 2026 per TARA's latest filing, from -$17.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$7.7 million in Q3 2022 and bottomed at -$39.0 million in Q4 2022.
• Historically, Profit After Tax has averaged -$13.3 million across 5 years, with a median of -$11.2 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 274.68% — and 2023, when it jumped 75.46%.
• Protara Therapeutics' Profit After Tax stood at -$39.0 million in 2022, then surged by 75.46% to -$9.6 million in 2023, then tumbled by 34.14% to -$12.8 million in 2024, then slumped by 34.91% to -$17.3 million in 2025, then retreated by 2.74% to -$17.8 million in 2026.
• Business Quant data shows TARA's Profit After Tax at -$17.8 million in Q1 2026, -$17.3 million in Q4 2025, and -$13.3 million in Q3 2025.